RPG Life Sciences Limited (NSE:RPGLIFE)
India · Delayed Price · Currency is INR 2,636.60
-18.20 (-0.69%)
Aug 21, 2026, 3:29 PM IST
RPG Life Sciences Ratios and Metrics
Market cap in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Total Valuation
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 21, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
| 43,607 | 30,725 | 37,735 | 25,279 | 11,585 | 9,269 | |
Market Cap Growth | 12.50% | -18.58% | 49.27% | 118.21% | 24.98% | 44.67% |
Enterprise Value | 41,063 | 28,489 | 36,475 | 24,260 | 10,780 | 8,672 |
Last Close Price | 2636.60 | 1839.52 | 2236.89 | 1483.63 | 671.73 | 528.52 |
Price Ratios
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 21, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
PE Ratio | 36.45 | 26.68 | 20.59 | 28.84 | 17.13 | 18.01 |
PS Ratio | 5.94 | 4.34 | 5.78 | 4.34 | 2.26 | 2.11 |
PB Ratio | 7.20 | 5.08 | 7.11 | 6.74 | 3.77 | 3.62 |
P/TBV Ratio | 7.30 | 5.14 | 7.43 | 7.29 | 4.22 | 4.19 |
P/FCF Ratio | - | - | 90.21 | 100.59 | 19.94 | 22.72 |
P/OCF Ratio | 77.18 | 54.38 | 48.47 | 26.79 | 12.76 | 14.32 |
EV Ratios
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 21, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
EV/Sales Ratio | 5.59 | 4.03 | 5.58 | 4.17 | 2.10 | 1.97 |
EV/EBITDA Ratio | 26.63 | 19.40 | 22.78 | 19.08 | 10.53 | 10.25 |
EV/EBIT Ratio | 30.90 | 22.64 | 26.17 | 21.84 | 12.24 | 12.26 |
EV/FCF Ratio | - | - | 87.20 | 96.54 | 18.56 | 21.26 |
Financial Efficiency
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 21, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Debt / Equity Ratio | 0.03 | 0.03 | - | - | 0 | 0.00 |
Debt / EBITDA Ratio | 0.13 | 0.14 | - | - | 0.00 | 0.01 |
Debt / FCF Ratio | - | - | - | - | 0 | 0.02 |
Net Debt / Equity Ratio | -0.42 | -0.42 | -0.50 | -0.34 | -0.37 | -0.27 |
Net Debt / EBITDA Ratio | -1.65 | -1.73 | -1.65 | -0.99 | -1.12 | -0.81 |
Net Debt / FCF Ratio | - | 28.71 | -6.33 | -5.01 | -1.98 | -1.69 |
Asset Turnover | - | 0.98 | 1.12 | 1.25 | 1.34 | 1.36 |
Inventory Turnover | - | 2.38 | 2.26 | 1.93 | 1.98 | 2.08 |
Quick Ratio | - | 2.50 | 3.00 | 1.35 | 1.50 | 1.34 |
Current Ratio | - | 3.48 | 3.88 | 2.28 | 2.57 | 2.58 |
Return on Equity (ROE) | - | 20.28% | 40.48% | 25.69% | 24.01% | 21.80% |
Return on Assets (ROA) | - | 10.84% | 14.88% | 14.89% | 14.41% | 13.65% |
Return on Invested Capital (ROIC) | 28.27% | 30.47% | 42.59% | 37.41% | 34.23% | 27.27% |
Return on Capital Employed (ROCE) | - | 19.90% | 25.90% | 29.10% | 27.80% | 26.70% |
Yields
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 21, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Earnings Yield | 2.74% | 3.75% | 4.86% | 3.47% | 5.84% | 5.55% |
FCF Yield | -0.20% | -0.29% | 1.11% | 0.99% | 5.01% | 4.40% |
Dividend Yield | 0.91% | 1.31% | 0.89% | 1.08% | 1.79% | 1.82% |
Payout Ratio | - | 34.46% | 14.44% | 22.64% | 23.48% | 23.14% |
Total Shareholder Return | 0.90% | 1.31% | 0.89% | 1.08% | 1.79% | 1.82% |